Skip to main content
SpringerLink
Log in

GP2017: An Adalimumab Biosimilar

  • Adis Biosimilar Brief
  • Published:
BioDrugs Aims and scope Submit manuscript

Abstract

GP2017 (adalimumab) is a biosimilar anti-TNF-α antibody. It is approved in the EU for use in all indications for which reference adalimumab is approved. GP2017 has similar physicochemical and functional properties to those of reference adalimumab, and the pharmacokinetic similarity of the agent has been shown in healthy male volunteers. GP2017 demonstrated clinical efficacy equivalent to that of reference adalimumab in patients with moderate to severe plaque psoriasis or rheumatoid arthritis; the tolerability, safety and immunogenicity profiles of the two agents were also similar. Multiple switching between GP2017 and reference adalimumab (up to four times) had no impact on efficacy, tolerability or immunogenicity. The role of reference adalimumab in the management of autoimmune inflammatory conditions is well established and GP2017 provides an effective biosimilar alternative for patients requiring adalimumab therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. European Medicines Agency. Hyrimoz: EU summary of product characteristics. 2018. http://www.ema.europa.eu. Accessed 30 Aug 2018.

  2. European Medicines Agency. Hefiya: EU summary of product characteristics. 2018. http://www.ema.europa.eu/. Accessed 8 Oct 2018.

  3. European Medicines Agency. Halimatoz: EU summary of product characteristics. 2018. http://www.ema.europa.eu. Accessed 8 Sept 2018.

  4. Abbvie Inc. Humira® (adalimumab) injection, for subcutaneous use: US prescribing information. 2018. http://www.fda.gov. Accessed 5 Oct 2018.

  5. European Medicines Agency. Humira (adalimumab): EU summary of product characteristics. 2018. http://www.ema.europa.eu. Accessed 5 Oct 2018.

  6. Schiestl M, Roesli C. Development and analytical characterization of GP2017: a proposed adalimumab biosimilar [abstract no. 627]. Am J Gastroenterol. 2016;111(Suppl 1):S289.

    Google Scholar 

  7. European Medicines Agency. Hyrimoz (adalimumab): EMA assessment report 2018. http://www.ema.europa.eu. Accessed 31 Aug 2018.

  8. Kronthaler U, Fritsch C, Hainzl O, et al. Comparative functional and pharmacological characterization of Sandoz proposed biosimilar adalimumab (GP2017): rationale for extrapolation across indications. Expert Opin Biol Ther. 2018;18(8):921–30.

    Article  CAS  PubMed  Google Scholar 

  9. Blauvelt A, Lacour JP, Fowler JF Jr, et al. Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches. Br J Dermatol. 2018;179(3):623–31.

    Article  CAS  PubMed  Google Scholar 

  10. Blauvelt A, Lacour JP, Fowler JF, et al. Long-term efficacy, safety, and immunogenicity data from a phase III confirmatory study comparing GP2017, a proposed biosimilar, with reference adalimumab [abstract no. 751]. Am J Gastroenterol. 2017;112(Suppl 1):S419.

    Google Scholar 

  11. Wiland P, Jeka S, Dokoupilova E, et al. A randomized, double-blind, parallel-group, multicenter study to compare the efficacy, safety and immunogenicity of a proposed adalimumab biosimilar (GP2017) with reference adalimumab in patients with moderate-to-severe active rheumatoid arthritis [abstract no. 1936]. Arthritis Rheumatol. 2018;70(Suppl 10).

  12. Jauch-Lembach J, Skerjanec A, Haliduola H, et al. Randomized, double-blind, single-dose, three-arm parallel trial to determine the pharmacokinetics and safety of GP2017, EU-and US-adalimumab in healthy male subjects [abstract no. 2443]. Arthritis Rheumatol. 2017;69(Suppl 10).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Springer, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand

    Young-A Heo

Authors
  1. Young-A Heo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Young-A Heo.

Ethics declarations

Conflict of interest

The preparation of this review was not supported by any external funding. During the peer review process, the manufacturer of GP2017 was also offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit. Young-A Heo is a salaried employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest.

Additional information

The manuscript was reviewed by: B. Jilma, Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria; P. Kurki, Department of Clinical Immunology, University of Helsinki, Helsinki, Finland.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Heo, YA. GP2017: An Adalimumab Biosimilar. BioDrugs 32, 635–638 (2018). https://doi.org/10.1007/s40259-018-0318-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40259-018-0318-x

Search

Navigation